Microbiotica's $45M Boost: A New Era for Gut Health?

Jan de Vries · 2026-10-16

Microbiotica, a British biopharma company, just gave us a reason to pay attention to the gut. They've closed a $45 million Series C round to push their precision microbiome medicine into Phase 2 trials for ulcerative colitis. It's a big deal for a field that's still finding its footing. ### The Deal That Got Everyone Talking The financing was led by British Business Bank, with participation from heavy hitters like Tencent, IP Group, and Cambridge Innovation Capital. All existing Series B investors joined in, which says a lot about their confidence. Tim Sharpington, Microbiotica's CEO, called it "an important next stage" and highlighted the progress they've made in turning their genomics platform into clinical-stage products. So what's the big deal? Their lead candidate, MB310, is an orally-dosed treatment that aims to modulate the gut microbiome to treat ulcerative colitis. In a Phase 1b study, it produced statistically significant clinical remission with no safety issues. That's the kind of result that makes investors sit up straight. ### Why Microbiome Therapeutics Matter Your gut is teeming with trillions of bacteria—a complex ecosystem that influences everything from digestion to immunity. When that ecosystem goes haywire, it can contribute to inflammatory bowel diseases like ulcerative colitis. Microbiotica's approach is to identify specific bacterial strains that promote healing and deliver them in a pill. They've built a powerful platform that combines a diverse microbiome culture collection, a proprietary human Reference Genome Database, and machine learning. By analyzing clinical trial data, they can pinpoint which bacteria are associated with better outcomes. It's like having a map of the gut's good guys. ### The Bigger Picture: A Biotech Funding Frenzy Microbiotica's round is part of a wave of European biotech investments in 2026. Here's a quick rundown: - Germany's mbiomics raised $13 million (€12 million), bringing its Series A to $32 million (€30 million). - UK's OutPost Bio secured $3.1 million (€2.9 million) for its microbiology modeling platform. - France's Bionyra Pharma nabbed $154 million (€143 million) for inflammatory disease treatments. - Paris-based Generare raised $21.5 million (€20 million) for microbial-genome drug discovery. - London's Alchemab Therapeutics received $31.5 million (€29.3 million) from British Business Bank. Add it all up, and you've got over $220 million (€207.2 million) in new financing—$268 million (€249.2 million) if you include Microbiotica's round. Clearly, investors see potential in bugs. > "We believe Microbiotica is emerging as a world leader in the development of microbiome therapeutics," said Carmine Circelli of British Business Bank. "Its Phase 1b study in ulcerative colitis produced statistically significant clinical remission, best in disease potential with no safety issues." ### What's Next for Microbiotica? The company plans to use the funds to take MB310 into Phase 2 trials. If those trials confirm the Phase 1b results, it could be a major breakthrough for the 1 in 100 Americans living with inflammatory bowel disease. Microbiotica was founded in 2016 as a spin-out from the Wellcome Sanger Institute and has already partnered with giants like MSD, Genentech, and Cancer Research UK. Dr. Sam Williams of IP Group, an early investor, said they've been "very impressed" with the progress. "There is an important opportunity to advance Microbiotica's precision microbiome approach into a larger clinical study," he noted. So keep an eye on this space. The bugs in your gut might just hold the key to treating some of our most stubborn diseases.